- Report
- August 2025
- 194 Pages
Global
From €3451EUR$3,939USD£2,978GBP
- Report
- December 2025
- 200 Pages
Global
From €2620EUR$2,990USD£2,261GBP
- Report
- January 2026
- 187 Pages
Global
From €3451EUR$3,939USD£2,978GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €2628EUR$3,000USD£2,268GBP
- Report
- June 2025
- 150 Pages
Global
From €2365EUR$2,699USD£2,041GBP
- Report
- April 2025
- 137 Pages
Asia Pacific
From €3023EUR$3,450USD£2,608GBP
- Report
- April 2025
- 136 Pages
Middle East, Africa
From €3023EUR$3,450USD£2,608GBP
- Report
- May 2024
- 131 Pages
Global
From €3504EUR$3,999USD£3,023GBP
- Report
- May 2024
- 132 Pages
Global
From €3504EUR$3,999USD£3,023GBP
- Report
- October 2023
- 145 Pages
Global
From €2760EUR$3,150USD£2,382GBP
- Report
- April 2023
- 180 Pages
Global
From €2847EUR$3,250USD£2,457GBP
- Report
- August 2024
- 80 Pages
Japan
From €3066EUR$3,500USD£2,646GBP
- Report
- May 2024
- 132 Pages
Global
From €3504EUR$3,999USD£3,023GBP
- Report
- February 2024
- 360 Pages
Global
From €6965EUR$7,950USD£6,011GBP
- Report
- December 2023
- 140 Pages
Global
From €3899EUR$4,450USD£3,364GBP
- Report
- July 2024
- 150 Pages
Global
From €3899EUR$4,450USD£3,364GBP
- Report
- November 2020
- 199 Pages
Global
€3943EUR$4,500USD£3,402GBP
- Report
- February 2026
- 50 Pages
Global
From €2322EUR$2,650USD£2,004GBP

Bimatoprost is a medication used to treat glaucoma and other optical disorders. It is a prostaglandin analog, meaning it works by increasing the outflow of fluid from the eye, reducing intraocular pressure. Bimatoprost is available as a topical ophthalmic solution, and is the only prostaglandin analog approved for the treatment of glaucoma and ocular hypertension. It is also used to treat hypotrichosis, a condition characterized by inadequate or thinning eyelashes.
Bimatoprost is a widely used medication in the optical disorders drugs market. It is the most commonly prescribed prostaglandin analog for glaucoma and ocular hypertension, and is also used off-label for other conditions. Bimatoprost is generally well-tolerated, with few side effects.
Some companies in the Bimatoprost market include Allergan, Sun Pharmaceuticals, and Pfizer. Show Less Read more